NASDAQ:DVAX Dynavax Technologies (DVAX) Stock Price, News & Analysis $11.03 +0.18 (+1.66%) (As of 09/6/2024 ET) Add Compare Share Share Today's Range$10.87▼$11.1050-Day Range$10.05▼$11.6152-Week Range$9.74▼$15.15Volume1.80 million shsAverage Volume2.11 million shsMarket Capitalization$1.44 billionP/E Ratio183.83Dividend YieldN/APrice Target$23.67 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Dynavax Technologies alerts: Email Address Dynavax Technologies MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.75 Rating ScoreUpside/Downside114.6% Upside$23.67 Price TargetShort InterestBearish14.46% of Shares Sold ShortDividend StrengthN/ASustainability-1.59Upright™ Environmental ScoreNews Sentiment0.71Based on 4 Articles This WeekInsider TradingN/AProj. Earnings Growth68.75%From $0.16 to $0.27 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.20 out of 5 starsMedical Sector136th out of 910 stocksPharmaceutical Preparations Industry48th out of 426 stocks 3.4 Analyst's Opinion Consensus RatingDynavax Technologies has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 3 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageDynavax Technologies has only been the subject of 2 research reports in the past 90 days.Read more about Dynavax Technologies' stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted14.46% of the outstanding shares of Dynavax Technologies have been sold short.Short Interest Ratio / Days to CoverDynavax Technologies has a short interest ratio ("days to cover") of 8.5.Change versus previous monthShort interest in Dynavax Technologies has recently increased by 5.81%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldDynavax Technologies does not currently pay a dividend.Dividend GrowthDynavax Technologies does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreDynavax Technologies has received a 74.16% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is false driven by its "Hepatitis B vaccines", "Clinical research services for infectious diseases", and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Dynavax Technologies is -1.59. Previous Next 2.6 News and Social Media Coverage News SentimentDynavax Technologies has a news sentiment score of 0.71. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.55 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Dynavax Technologies this week, compared to 3 articles on an average week.Search InterestOnly 1 people have searched for DVAX on MarketBeat in the last 30 days. This is a decrease of -75% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Dynavax Technologies insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 2.98% of the stock of Dynavax Technologies is held by insiders.Percentage Held by Institutions96.96% of the stock of Dynavax Technologies is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Dynavax Technologies' insider trading history. Previous Next 1.9 Earnings and Valuation Earnings GrowthEarnings for Dynavax Technologies are expected to grow by 68.75% in the coming year, from $0.16 to $0.27 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Dynavax Technologies is 183.83, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 127.80.Price to Earnings Ratio vs. SectorThe P/E ratio of Dynavax Technologies is 183.83, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 112.46.Price to Book Value per Share RatioDynavax Technologies has a P/B Ratio of 2.25. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Dynavax Technologies' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto 101 MediaPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying with both fists. They know it's only a matter of time before another bull run. Now, Crypto Insiders Are Scooping up Lesser-Known Coins and Making Serious BankGo here to get full details on this crypto now. About Dynavax Technologies Stock (NASDAQ:DVAX)Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. The company also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B. Dynavax Technologies Corporation has a collaboration agreement with Valneva Scotland Limited; Zhejiang Clover Biopharmaceuticals, Inc.; Clover Biopharmaceuticals (Hong Kong) Co., Limited; Biological E. Limited; PT Bio Farma; Medigen Vaccine Biologics; and Serum Institute of India Pvt. Ltd. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. The company was incorporated in 1996 and is headquartered in Emeryville, California.Read More DVAX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart DVAX Stock News HeadlinesSeptember 5 at 7:37 PM | seekingalpha.comDynavax Technologies: Slow And Steady Wins The RaceAugust 30, 2024 | money.usnews.comDynavax Technologies Corp.September 7, 2024 | Sasco Gold LLC (Ad)Say Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." I believe the American people deserve to control the fate of their own life savings which is why I had my team put together our latest guide to protect your hard-earned wealth before it's too late... August 28, 2024 | ca.finance.yahoo.comDVAX Sep 2024 10.000 putAugust 23, 2024 | seekingalpha.comDynavax Technologies: A Two Trick Pony Operating With A Single TrickAugust 10, 2024 | finance.yahoo.comDynavax Technologies Corporation Just Recorded A 28% EPS Beat: Here's What Analysts Are Forecasting NextAugust 7, 2024 | msn.comDynavax Technologies Corporation (NASDAQ:DVAX) Q2 2024 Earnings Call TranscriptAugust 7, 2024 | markets.businessinsider.comDynavax’s Market Dominance and Buoyant Growth Prospects Affirm Buy RatingSeptember 7, 2024 | Sasco Gold LLC (Ad)Say Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." I believe the American people deserve to control the fate of their own life savings which is why I had my team put together our latest guide to protect your hard-earned wealth before it's too late... August 7, 2024 | markets.businessinsider.comDynavax Stock Hold Rating Maintained Amidst Sales Uncertainty and Pipeline RisksAugust 7, 2024 | markets.businessinsider.comDynavax’s Strong Growth and Market Share Expansion Drive Buy RatingAugust 7, 2024 | msn.comDynavax Technologies (DVAX) Q2 2024 Earnings Call TranscriptAugust 6, 2024 | investorplace.comDVAX Stock Earnings: Dynavax Technologies Beats EPS, Misses Revenue for Q2 2024August 6, 2024 | prnewswire.comDynavax Reports Second Quarter 2024 Financial Results and Provides Business UpdatesAugust 6, 2024 | markets.businessinsider.comDynavax Technologies is about to announce earnings — here's what Wall Street expectsJuly 23, 2024 | prnewswire.comDynavax to Report Second Quarter 2024 Financial Results and Host Conference Call on August 6, 2024June 27, 2024 | prnewswire.comDynavax Initiates Phase 1/2 Study of Novel Shingles Vaccine ProgramMay 28, 2024 | prnewswire.comDynavax to Present at Upcoming Investor ConferencesSee More Headlines Receive DVAX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Dynavax Technologies and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/06/2024Today9/07/2024Next Earnings (Estimated)11/07/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryBiotechnology Current SymbolNASDAQ:DVAX CUSIP26815810 CIK1029142 Webwww.dynavax.com Phone(510) 848-5100Fax510-848-1327Employees408Year Founded1996Price Target and Rating Average Stock Price Target$23.67 High Stock Price Target$29.00 Low Stock Price Target$15.00 Potential Upside/Downside+114.6%Consensus RatingModerate Buy Rating Score (0-4)2.75 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)$0.06 Trailing P/E Ratio183.83 Forward P/E Ratio68.94 P/E GrowthN/ANet Income$-6,390,000.00 Net Margins6.88% Pretax Margin7.43% Return on Equity2.76% Return on Assets1.73% Debt Debt-to-Equity Ratio0.35 Current Ratio14.18 Quick Ratio13.18 Sales & Book Value Annual Sales$249.69 million Price / Sales5.78 Cash FlowN/A Price / Cash FlowN/A Book Value$4.91 per share Price / Book2.25Miscellaneous Outstanding Shares130,892,000Free Float126,991,000Market Cap$1.44 billion OptionableOptionable Beta1.37 Social Links Investing Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free Report Key ExecutivesMr. Ryan Spencer (Age 46)CEO, Interim CFO & Director Comp: $1.49MMr. David F. Novack (Age 62)President & COO Comp: $1.01MDr. Robert Janssen M.D. (Age 70)Chief Medical Officer and Senior VP of Clinical Development, Medical & Regulatory Affairs Comp: $861.52kMs. Kelly MacDonald (Age 40)Senior VP & CFO (Leave of Absence) Comp: $788.55kMr. Justin BurgessChief Accounting Officer & ControllerMr. Jeff P. Coon (Age 61)Senior VP & Chief Human Resources Officer Mr. Paul CoxVP of Investor Relations & Corporate CommunicationsMr. John L. Slebir (Age 58)Senior VP & General Counsel Mr. Donn CasaleSenior VP & Chief Commercial OfficerDr. Dong YuSenior Vice President of Vaccine ResearchMore ExecutivesKey CompetitorsProthenaNASDAQ:PRTAG1 TherapeuticsNASDAQ:GTHXUroGen PharmaNASDAQ:URGNPuma BiotechnologyNASDAQ:PBYIMarinus PharmaceuticalsNASDAQ:MRNSView All CompetitorsInsiders & InstitutionsSanctuary Advisors LLCBought 16,243 shares on 9/5/2024Ownership: 0.012%Point72 Asset Management L.P.Sold 90,000 shares on 8/19/2024Ownership: 0.000%Algert Global LLCBought 12,496 shares on 8/16/2024Ownership: 0.010%Millennium Management LLCBought 1,568,553 shares on 8/15/2024Ownership: 1.198%The Manufacturers Life Insurance Company Bought 4,069 shares on 8/15/2024Ownership: 0.052%View All Insider TransactionsView All Institutional Transactions DVAX Stock Analysis - Frequently Asked Questions How have DVAX shares performed this year? Dynavax Technologies' stock was trading at $13.98 at the start of the year. Since then, DVAX shares have decreased by 21.1% and is now trading at $11.03. View the best growth stocks for 2024 here. How were Dynavax Technologies' earnings last quarter? Dynavax Technologies Co. (NASDAQ:DVAX) released its quarterly earnings data on Tuesday, August, 6th. The biopharmaceutical company reported $0.08 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.06 by $0.02. The biopharmaceutical company had revenue of $73.80 million for the quarter, compared to analyst estimates of $76.92 million. Dynavax Technologies had a net margin of 6.88% and a trailing twelve-month return on equity of 2.76%. What is Eddie Gray's approval rating as Dynavax Technologies' CEO? 13 employees have rated Dynavax Technologies Chief Executive Officer Eddie Gray on Glassdoor.com. Eddie Gray has an approval rating of 59% among the company's employees. This puts Eddie Gray in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. 61.0% of employees surveyed would recommend working at Dynavax Technologies to a friend. Who are Dynavax Technologies' major shareholders? Top institutional investors of Dynavax Technologies include Federated Hermes Inc. (5.46%), Chicago Capital LLC (4.28%), Dimensional Fund Advisors LP (3.00%) and Renaissance Technologies LLC (1.89%). Insiders that own company stock include Andrew A F Hack, Ryan Spencer, Robert Janssen, Francis Cano, David F Novack and Justin Burgess. View institutional ownership trends. How do I buy shares of Dynavax Technologies? Shares of DVAX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Dynavax Technologies own? Based on aggregate information from My MarketBeat watchlists, some other companies that Dynavax Technologies investors own include Puma Biotechnology (PBYI), BioMarin Pharmaceutical (bmrn), (MDVN) (MDVN), Incyte (incy), Sorrento Therapeutics (SRNE), Vaxart (VXRT) and Matinas BioPharma (MTNB). This page (NASDAQ:DVAX) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial inde...Golden Crest | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredChina Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a populat...True Gold Republic | SponsoredTrump’s weapon lurks in abandoned AmericaUnemployment is sky-high, wages are at record lows. Addiction has overwhelmed these once thriving coal towns. ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Dynavax Technologies Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Dynavax Technologies With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free DVAX Stock Alerts